| T
|
| Drug |
CYP interaction |
Clinical consequences |
| tacrine (cholinesterase inhibitor for Alzheimer's)
| CYP1A2 : metabolism
| ? (may need to decrease dosage if given with cimetidine)
|
| tacrolimus (=FK 506)
| CYP3A4 : METABOLISM
| ? toxicity with inhibition (quinidine, omeprazole, sulindac),
and also nifedipine
as well as HIV protease inhibitors (incl. saquinavir, nelfinavir)
minor effect from theophylline, diclofenac, indomethacin, phenylbutazone, and
cimetidine [Res Commun Mol Pathol Pharmacol 1996 Jan;91(1):57-64]
|
| tamoxifen
| 2C9 : metabolism
| ?
|
3A4 : metabolism
(? also minor metabolism by other CYPs, NOT 2D6)
| ?
|
| taxoids (paclitaxel, docetaxel,'Taxol')
| CYP3A4 : metabolism, also CYP2C8 [Bull Cancer 1997 Feb;84(2):125-33],
[Eur J Drug Metab Pharmacokinet 1998 Jul-Sep;23(3):417-24]
| ?
|
| temazepam
| 3A4 : 'minor' metabolism
| NO significant interaction with 3A4 inhibitors!!
[Ther Drug Monit 1996 Apr;18(2):124-7] (e.g.
itraconazole,
erythromycin)
|
| teniposide
| 2C19 : metabolism
| ?
|
| 2C9 : ? INHIBITS
| ?
|
| 3A4: metabolism
| ?
|
| terbinafine
| CYP2D6 : INHIBITS (potent)
| interactions with e.g. nortriptyline, desipramine,
perphenazine, metoprolol, encainide, propafenone
|
| terfenadine
| CYP3A4 : METABOLISM
| 3A4 inhibition gives fatal arrhythmias : block IKr [Drug Saf 1999;21 Suppl 1:11-8]
|
| 3A4: inhibits (IC50 23 µM)
| ?
|
| testosterone
| CYP3A4 : metabolism
| ?
|
| theophylline (with ethylenediamine = aminophyllin)
| CYP3A4 : METABOLISM
| TOXICITY with eg. "erythromycin, troleandromycin,
roxithromycin,
enoxacin, ciprofloxacin, pefloxacin, norfloxacin, ofloxacin, fluoroquinolone
T-3262, pipemidic acid, cimetidine, etintidine, propranolol, verapamil, diltiazem, nifedipine,
furosemide, some oral contraceptives, viloxazine, allopurinol, ticlopidine,
idrocilamide, thiabendazole, disulfiram, influenza- and BCG-vaccination, interferon, and caffeine"
[Clin Pharmacokinet 1991 Jan;20(1):66-80]
LOW levels with "isoprenaline (isoproterenol), terbutaline, some corticosteroids, phenytoin,
phenobarbital, activated charcoal, felodipine moricizine, benzodiazepines and sulfinpyrazone"
|
| CYP1A2 : metabolism
| possible interaction with 1A2 inhibitors
|
| 2E1 : metabolism
| ?
|
| thiopental
| ? 2E1 INHIBITS
at concentrations of 0.3mM
| ?
|
| thioridazine (See also Antipsychotics)
| CYP2D6 : metabolism
| fluoxetine massively increases levels! [Exp Toxicol Pathol 1999 Jul;51(4-5):309-14]
|
| 2D6 : INHIBITS (IC50 2.7 µM)
| e.g. inhibition of codeine effect ,
interaction with mianserin
|
| tiagabine
| 3A4 : metabolism
| NO significant interaction with oral contraceptives [Clin Pharmacokinet 2000 Apr;38(4):355-65]
or (apparently) other CYP-metabolised agents
|
| ticlopidine
| CYP2C19 : INHIBITS
| ?
|
| 1A2 : INHIBITS
| ?
|
| timolol (See also beta blockers)
| 2D6 : metabolism
| interaction potential
|
| tirilazad
| CYP3A4 : metabolism
| ?
|
| tobacco - see smoking
|
| tolbutamide
| CYP2C9 : metabolism
| prolonged hypoglycaemia occurs with low 2C9 activity
|
| CYP2E1 : metabolism
| ?
|
| 2C19 : may also participate in metabolism
|
|
| tolterodine
| CYP2D6 : metabolism
| ?
|
| topiramate
| 2C19 : INHIBITS
| ?
|
| torsemide {= torasemide} - a diuretic.
| CYP2C9 : metabolism <--[Biochem Biophys Res Commun 1999 Jan 27;254(3):628-31],
[J Pharmacol Exp Ther 1995 Mar;272(3):1076-81]->
| ?
|
| tramadol
| CYP2D6 : activates -a prodrug.
| ineffective with low 2D6 activity
|
| tranylcypromine
| inhibits several CYPs:
CYP2A6, CYP2C9, CYP2C19, and CYP2E1
| ?
|
| trazodone
| CYP2D6 : metabolism
| ? (no interaction with haloperidol)
|
| 3A4 : METABOLISM [Biol Psychiatry 2000 Apr 1;47(7):655-61]
| ? interaction with eg ritonavir, ..
|
| triazolam (See also Benzodiazepines)
| CYP3A4 : metabolism
(also 3A5, 3A7)
| excessive sedation with 3A4 inhibitors eg itraconazole,
grapefruit juice
|
| Tricyclic antidepressants (see also antidepressants,
and individual drugs)
| CYP1A2 : low activity
| ?
|
| CYP2C8 : metabolised
| ?
|
| CYP2C19 : metabolised
| ?
|
| CYP2D6 : metabolism
| ?
|
| CYP2D6 : INHIBITS
| ?
|
| CYP3A4 : metabolism
| ?
|
| tri-iodothyronine, T3, (thus T4)
| 3A4 : inhibited
|
|
| tripellenamine (1st generation antihistamine)
| 2D6 : inhibits (Ki ~ 4-6 µM)
| ?
|
| trofosfamide
| 3A4 : METABOLISM [Cancer Chemother Pharmacol 1999;44(4):327-34]
| potential for interaction
|
| troglitazone (thiazolidinedione hypoglycaemic)
| 3A4 : INDUCED [Clin Pharmacokinet 1999 Aug;37(2):91-104]
| lowers cyclosporin,
terfenadine, fenoxfenadine, atorvastatin;
oral contraceptives
|
| troleandromycin (triacetyloleandomycin)
| 3A4 : INHIBITS
| many potential interactions
- see also macrolides
|
| tropisetron (5HT3 antagonist)
| 2D6 : metabolism
| potential for interaction with 2D6 inhibitors
|
| trospium chloride (atropinergic for incontinence)
| 2D6 : inhibits (Ki 20-51 µM)
| ?
|